Ravenol

Ravenol may be available in the countries listed below.

Ingredient matches for Ravenol

Sulodexide

Sulodexide is reported as an ingredient of Ravenol in the following countries:

• Italy

International Drug Name Search

Salislon

Salislon may be available in the countries listed below.

Ingredient matches for Salislon

Cefadroxil

Cefadroxil is reported as an ingredient of Salislon in the following countries:

• Japan

International Drug Name Search

Tarizart

Tarizart may be available in the countries listed below.

Ingredient matches for Tarizart

Ofloxacin

Ofloxacin is reported as an ingredient of Tarizart in the following countries:

• Japan

International Drug Name Search

Fansulide

Fansulide may be available in the countries listed below.

Ingredient matches for Fansulide

Nimesulide

Nimesulide is reported as an ingredient of Fansulide in the following countries:

• Italy

International Drug Name Search

Fractopon

Fractopon may be available in the countries listed below.

Ingredient matches for Fractopon

Aceclofenac

Aceclofenac is reported as an ingredient of Fractopon in the following countries:

• Greece

International Drug Name Search

Cropropamide

In some countries, this medicine may only be approved for veterinary use.

Scheme

Prop.INN

CAS registry number (Chemical Abstracts Service)

0000633-47-6

Chemical Formula

C13-H24-N2-O2

Molecular Weight

240

Therapeutic Category

Analeptic

Chemical Name

2-Butenamide, N-[1-[(dimethylamino)carbonyl]propyl]-N-propyl-

Foreign Names

• Cropropamidum (Latin)
• Cropropamid (German)
• Cropropamide (French)
• Cropropamida (Spanish)

Generic Name

• Cropropamide (OS: DCF, DCIT, BAN)

Brand Names

• Micoren (Cropropamide and Crotetamide)
  Novartis Consumer Health, Italy



• Respirot (Cropropamide and Crotetamide (veterinary use))
  Novartis Animal Health, Norway; Novartis Santé Animale, France; Novartis Tiergesundheit, Switzerland

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
OS	Official Synonym
Prop.INN	Proposed International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Cétornan

Cétornan may be available in the countries listed below.

Ingredient matches for Cétornan

Ornithine

Ornithine oxoglurate (a derivative of Ornithine) is reported as an ingredient of Cétornan in the following countries:

• Algeria


• France

International Drug Name Search

Drakern

Drakern may be available in the countries listed below.

Ingredient matches for Drakern

Ketotifen

Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Drakern in the following countries:

• Japan

International Drug Name Search

Thiogamma Turbo-Set

Thiogamma Turbo-Set may be available in the countries listed below.

Ingredient matches for Thiogamma Turbo-Set

Thioctic Acid

Thioctic Acid meglumine (a derivative of Thioctic Acid) is reported as an ingredient of Thiogamma Turbo-Set in the following countries:

• Germany

International Drug Name Search

Terazosina Hexal

Terazosina Hexal may be available in the countries listed below.

Ingredient matches for Terazosina Hexal

Terazosin

Terazosin hydrochloride (a derivative of Terazosin) is reported as an ingredient of Terazosina Hexal in the following countries:

• Italy

International Drug Name Search

Siphene

Siphene may be available in the countries listed below.

Ingredient matches for Siphene

Clomifene

Clomifene citrate (a derivative of Clomifene) is reported as an ingredient of Siphene in the following countries:

• India

International Drug Name Search

Telavancin Hydrochloride

Telavancin Hydrochloride may be available in the countries listed below.

Ingredient matches for Telavancin Hydrochloride

Telavancin

Telavancin Hydrochloride (USAN) is known as Telavancin in the US.

International Drug Name Search

Glossary

USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Uroxatral

Uroxatral is a brand name of alfuzosin, approved by the FDA in the following formulation(s):

UROXATRAL (alfuzosin hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: June 12, 2003
  
  Strength(s): 10MG ^[RLD][AB]

Has a generic version of Uroxatral been approved?

A generic version of Uroxatral has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Uroxatral and have been approved by the FDA:

alfuzosin hydrochloride tablet, extended release; oral

• 
  Manufacturer: APOTEX INC
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: INVAGEN PHARMS
  
  Approval date: January 17, 2012
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: SUN PHARMA GLOBAL
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]


• 
  Manufacturer: TORRENT PHARMS
  
  Approval date: July 18, 2011
  
  Strength(s): 10MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uroxatral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Alfuzosine compositions and use
  Patent 4,661,491
  Issued: April 28, 1987
  Inventor(s): Regnier; Francois
  Assignee(s): Synthelabo
  A method for treating humans or non-human animals for dysuria comprising administering an effective non-toxic amount of alfuzosine or a pharmaceutically acceptable salt thereof to a human or non-human animal suffering dysuria.
  
  Patent expiration dates:
  
  
  • July 18, 2011
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Tablet with controlled release of alfuzosine chlorhydrate
  Patent 6,149,940
  Issued: November 21, 2000
  Inventor(s): Maggi; Lauretta & Conte; Ubaldo & Grenier; Pascal & Vergnault; Guy & Dufour; Alain & Jarreau; Fran.cedilla.ois Xavier & Rauch-Desanti; Clemence
  Assignee(s): Synthelabo
  Jagotec AB
  Pharmaceutical tablet which consists of: a) a first layer having the property of swelling considerably and quickly on contact with aqueous biological fluids, the first layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers, and b) a second layer adjacent to the first layer being formulated with hydrophilic polymers and with other auxiliary substances in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period.
  
  Patent expiration dates:
  
  
  • August 22, 2017
    
  
  
  
  • February 22, 2018
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 15, 2013 - LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
  
  
  • June 15, 2014 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Uroxatral Consumer Information (Drugs.com)
• Uroxatral Consumer Information (Wolters Kluwer)
• Uroxatral Consumer Information (Cerner Multum)
• Uroxatral Advanced Consumer Information (Micromedex)
• Uroxatral AHFS DI Monographs (ASHP)
• Alfuzosin Consumer Information (Wolters Kluwer)
• Alfuzosin Consumer Information (Cerner Multum)
• Alfuzosin Advanced Consumer Information (Micromedex)
• Alfuzosin Hydrochloride AHFS DI Monographs (ASHP)

Zidicef

Zidicef may be available in the countries listed below.

Ingredient matches for Zidicef

Ceftazidime

Ceftazidime is reported as an ingredient of Zidicef in the following countries:

• Bangladesh

International Drug Name Search

Diazepam Alter

Diazepam Alter may be available in the countries listed below.

Ingredient matches for Diazepam Alter

Diazepam

Diazepam is reported as an ingredient of Diazepam Alter in the following countries:

• Italy

International Drug Name Search

Droxia

In the US, Droxia (hydroxyurea systemic) is a member of the drug class antimetabolites and is used to treat Anemia - Sickle Cell, Chronic Myelogenous Leukemia, Polycythemia Vera and Solid Tumors.

US matches:

• Droxia

Ingredient matches for Droxia

Hydroxycarbamide

Hydroxycarbamide is reported as an ingredient of Droxia in the following countries:

• United States

International Drug Name Search

Siozwo Nasengel

Siozwo Nasengel may be available in the countries listed below.

Ingredient matches for Siozwo Nasengel

Xylometazoline

Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Siozwo Nasengel in the following countries:

• Germany

International Drug Name Search

Duragesic-75

See also: Generic Duragesic-100, Generic Duragesic-12, Generic Duragesic-25, Generic Duragesic-50

Duragesic-75 is a brand name of fentanyl, approved by the FDA in the following formulation(s):

DURAGESIC-75 (fentanyl - film, extended release; transdermal)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: August 7, 1990
  
  Strength(s): 75MCG/HR ^[AB]

Has a generic version of Duragesic-75 been approved?

Yes. The following products are equivalent to Duragesic-75:

FENTANYL-75 (fentanyl film, extended release; transdermal)

• 
  Manufacturer: ACTAVIS
  
  Approval date: August 20, 2007
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: LAVIPHARM LABS
  
  Approval date: August 4, 2006
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: MALLINCKRODT INC
  
  Approval date: February 9, 2011
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: MYLAN TECHNOLOGIES
  
  Approval date: January 28, 2005
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: NOVEN
  
  Approval date: October 16, 2009
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: TEVA PHARMS
  
  Approval date: October 20, 2008
  
  Strength(s): 75MCG/HR ^[AB]


• 
  Manufacturer: WATSON LABS
  
  Approval date: August 20, 2007
  
  Strength(s): 75MCG/HR ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duragesic-75. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Duragesic-75.

See also...

• Duragesic-75 skin patch Consumer Information (Cerner Multum)
• Fentanyl Consumer Information (Drugs.com)
• Fentanyl Consumer Information (Wolters Kluwer)
• Fentanyl Lozenge Consumer Information (Wolters Kluwer)
• Fentanyl Patch Consumer Information (Wolters Kluwer)
• Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
• Fentanyl Spray Consumer Information (Wolters Kluwer)
• Fentanyl Tablet Consumer Information (Wolters Kluwer)
• Fentanyl buccal Consumer Information (Cerner Multum)
• Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
• Fentanyl nasal Consumer Information (Cerner Multum)
• Fentanyl sublingual Consumer Information (Cerner Multum)
• Fentanyl transdermal device Consumer Information (Cerner Multum)
• Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
• Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
• Fentanyl Nasal Advanced Consumer Information (Micromedex)
• Fentanyl Transdermal Advanced Consumer Information (Micromedex)
• Fentanyl Citrate AHFS DI Monographs (ASHP)

Pentamol

Pentamol may be available in the countries listed below.

Ingredient matches for Pentamol

Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Pentamol in the following countries:

• Germany

International Drug Name Search

Scabicin

Scabicin may be available in the countries listed below.

Ingredient matches for Scabicin

Crotamiton

Crotamiton is reported as an ingredient of Scabicin in the following countries:

• Israel


• Portugal

International Drug Name Search

Actimmune

In the US, Actimmune (interferon gamma-1b systemic) is a member of the drug class interferons and is used to treat Chronic Granulomatous Disease, Cutaneous T-cell Lymphoma, Idiopathic Pulmonary Fibrosis, Osteopetrosis and Rheumatoid Arthritis.

US matches:

• Actimmune

Ingredient matches for Actimmune

Interferon gamma

Interferon gamma Interferon gamma-1b (a derivative of Interferon gamma) is reported as an ingredient of Actimmune in the following countries:

• United States

International Drug Name Search

Silvamed

Silvamed may be available in the countries listed below.

Ingredient matches for Silvamed

Sulfadiazine

Sulfadiazine silver (a derivative of Sulfadiazine) is reported as an ingredient of Silvamed in the following countries:

• Turkey

International Drug Name Search

Renadinac

Renadinac may be available in the countries listed below.

Ingredient matches for Renadinac

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Renadinac in the following countries:

• Indonesia

International Drug Name Search

Nitrong

In the US, Nitrong is a member of the following drug classes: antianginal agents, vasodilators and is used to treat Angina, Angina Pectoris Prophylaxis, Heart Attack, Heart Failure and High Blood Pressure.

Ingredient matches for Nitrong

Nitroglycerin

Nitroglycerin is reported as an ingredient of Nitrong in the following countries:

• Georgia


• Greece


• Latvia


• Lithuania

International Drug Name Search

Dilabar

Dilabar may be available in the countries listed below.

Ingredient matches for Dilabar

Captopril

Captopril is reported as an ingredient of Dilabar in the following countries:

• Spain

International Drug Name Search

Rybix ODT

Generic Name: tramadol (TRAM a dol)

Brand Names: ConZip, Rybix ODT, Ryzolt, Ultram, Ultram ER

What is Rybix ODT (tramadol)?

Tramadol is a narcotic-like pain reliever.

Tramadol is used to treat moderate to severe pain. Tramadol extended-release is used to treat moderate to severe chronic pain when treatment is needed around the clock.

Tramadol may also be used for purposes not listed in this medication guide.

What is the most important information I should know about Rybix ODT (tramadol)?

You should not take tramadol if you are allergic to it, if you have ever been addicted to drugs or alcohol, or if you have ever attempted suicide. Do not take tramadol while you are intoxicated (drunk) or taking any of the following: alcohol or street drugs, narcotic pain medicine, sedatives or tranquilizers, or medicine for depression, anxiety, or mental illness.

Seizures (convulsions) have occurred in some people taking tramadol. Tramadol may be more likely to cause a seizure if you have a history of seizures or head injury, a metabolic disorder, or if you are taking certain medicines such as antidepressants, muscle relaxers, narcotic, or medicine for nausea and vomiting.

Seek emergency medical attention if you think you have used too much of this medicine. A tramadol overdose can be fatal. Tramadol may be habit-forming and should be used only by the person it was prescribed for. Keep the medication in a secure place where others cannot get to it. Do not crush the tramadol tablet. This medicine is for oral (by mouth) use only. Powder from a crushed tablet should not be inhaled or diluted with liquid and injected into the body. Using this medicine by inhalation or injection can cause life-threatening side effects, overdose, or death.

What should I discuss with my healthcare provider before taking Rybix ODT (tramadol)?

You should not take tramadol if you are allergic to it, if you have ever been addicted to drugs or alcohol, or if you have ever attempted suicide.

Do not take tramadol while you are intoxicated (drunk) or taking any of the following:

• 
  

  alcohol or street drugs;

  
  


• 
  

  narcotic pain medicine;

  
  


• 
  

  sedatives or tranquilizers (such as Valium);

  
  


• 
  

  medicine for depression or anxiety; or

  
  


• 
  

  medicine for mental illness (such as bipolar disorder, schizophrenia).

  
  

Seizures have occurred in some people taking tramadol. Talk with your doctor about your seizure risk, which may be higher if you have:

• 
  

  a history of drug or alcohol addiction;

  
  


• 
  

  a history of epilepsy or other seizure disorder;

  
  


• 
  

  a history of head injury;

  
  


• 
  

  a metabolic disorder; or

  
  


• 
  

  if you are also taking an antidepressant, muscle relaxer, narcotic, antipsychotic, or medicine for nausea and vomiting.

  
  

To make sure you can safely take tramadol, tell your doctor if you have any of these other conditions:

• 
  

  kidney disease (or if you are on dialysis);

  
  


• 
  

  cirrhosis or other liver disease;

  
  


• 
  

  a stomach disorder; or

  
  


• 
  

  a history of depression, mental illness, or thoughts of suicide.

  
  

Tramadol may be habit forming and should be used only by the person it was prescribed for. Never share tramadol with another person, especially someone with a history of drug abuse or addiction. Keep the medication in a place where others cannot get to it. FDA pregnancy category C. It is not known whether tramadol will harm an unborn baby. Tramadol may cause serious or fatal side effects in a newborn if the mother uses the medication during pregnancy or labor. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. Tramadol can pass into breast milk and may harm a nursing baby. You should not breast-feed while you are taking tramadol. Do not give this medication to anyone younger than 16 years old without the advice of a doctor.

Rybix ODT may contain phenylalanine. Talk to your doctor before using this form of tramadol if you have phenylketonuria (PKU).

How should I take Rybix ODT (tramadol)?

Take exactly as prescribed. Never take tramadol in larger amounts, or for longer than recommended by your doctor. Follow the directions on your prescription label. Tell your doctor if the medicine seems to stop working as well in relieving your pain.

Tramadol can be taken with or without food, but take it the same way each time.

Do not crush, chew, or break a tramadol tablet. Swallow it whole. Breaking the pill may cause too much of the drug to be released at one time. This medicine is for oral (by mouth) use only. Powder from a crushed tablet should not be inhaled or diluted with liquid and injected into the body. Using this medicine by inhalation or injection can cause life-threatening side effects, overdose, or death.

To take tramadol orally disintegrating tablets (Rybix ODT):

• 
  

  Keep the tablet in its blister pack until you are ready to take it.

  
  


• 
  

  Using dry hands, remove the tablet and place it in your mouth. It will begin to dissolve right away.

  
  


• 
  

  Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.

  
  


• 
  

  Swallow several times as the tablet dissolves. If desired, you may drink liquid to help swallow the dissolved tablet.

  
  

If you use the tramadol extended-release tablet, the tablet shell may pass into your stools (bowel movements). This is normal and does not mean that you are not receiving enough of the medicine.

Do not stop using tramadol suddenly, or you could have unpleasant withdrawal symptoms. Talk to your doctor about how to avoid withdrawal symptoms when stopping the medication. Store at room temperature away from moisture and heat.

Keep track of the amount of medicine used from each new bottle. Tramadol is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. A tramadol overdose can be fatal.

Overdose symptoms may include extreme drowsiness, shallow breathing, muscle weakness, slow heartbeat, cold or clammy skin, fainting, or seizure.

What should I avoid while taking Rybix ODT (tramadol)?

Do not drink alcohol. It may cause a dangerous decrease in your breathing when used together with tramadol. Tramadol may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Rybix ODT (tramadol) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using tramadol and call your doctor at once if you have any of these serious side effects:

• 
  

  agitation, hallucinations, fever, fast heart rate, overactive reflexes, nausea, vomiting, diarrhea, loss of coordination, fainting;

  
  


• 
  

  seizure (convulsions);

  
  


• 
  

  a red, blistering, peeling skin rash; or

  
  


• 
  

  shallow breathing, weak pulse.

  
  

Less serious side effects may include:

• 
  

  dizziness, spinning sensation;

  
  


• 
  

  constipation, upset stomach;

  
  


• 
  

  headache;

  
  


• 
  

  drowsiness; or

  
  


• 
  

  feeling nervous or anxious.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Rybix ODT (tramadol)?

You may be more likely to have a seizure (convulsions) if you take tramadol while you are using certain other medicines. Do not take tramadol without telling your doctor if you also use any of the following medications:

• 
  

  an MAO inhibitor such as isocarboxazid (Marplan), tranylcypromine (Parnate), phenelzine (Nardil), or selegiline (Eldepryl, Emsam); or

  
  


• 
  

  an antidepressant such as amitriptyline (Elavil, Vanatrip), citalopram (Celexa), clomipramine (Anafranil), desipramine (Norpramin), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), imipramine (Tofranil), nortriptyline (Pamelor), paroxetine (Paxil), or sertraline (Zoloft).

  
  

Cold or allergy medicine, sleeping pills, muscle relaxers, and medicine for seizures or anxiety can add to sleepiness caused by tramadol. Tell your doctor if you regularly use any of these medicines, or any other pain medication.

Tell your doctor about all other medicines you use, especially:

• 
  

  carbamazepine (Carbatrol, Equetro, Tegretol);

  
  


• 
  

  lithium (Eskalith, LithoBid);

  
  


• 
  

  ADHD medications (Adderall, Ritalin, Strattera);

  
  


• 
  

  an antibiotic such as clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole), linezolid (Zyvox), rifampin (Rifadin, Rimactane, Rifater); or telithromycin (Ketek);

  
  


• 
  

  antifungal medication such as clotrimazole (Mycelex Troche), itraconazole (Sporanox), ketoconazole (Nizoral), miconazole (Oravig), or voriconazole (Vfend);

  
  


• 
  

  cancer medications such as gefitinib (Iressa), imatinib (Gleevec), or nilotinib (Tasigna);

  
  


• 
  

  a heart rhythm medication such as amiodarone (Cordarone, Pacerone), flecainide (Tambocor), propafenone (Rythmol), or quinidine (Quin-G);

  
  


• 
  

  heart or blood pressure medication such as diltiazem (Cartia, Cardizem), felodipine (Plendil), nifedipine (Nifedical, Procardia), verapamil (Calan, Covera, Isoptin, Verelan), and others;

  
  


• 
  

  HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), saquinavir (Invirase), or ritonavir (Norvir, Kaletra); or

  
  


• 
  

  migraine headache medicine such as sumatriptan (Imitrex, Treximet).

  
  

This list is not complete and there are many other drugs that can interact with tramadol. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.

More Rybix ODT resources

• Rybix ODT Side Effects (in more detail)
• Rybix ODT Use in Pregnancy & Breastfeeding
• Rybix ODT Drug Interactions
• 0 Reviews for Rybix ODT - Add your own review/rating

• Rybix ODT Prescribing Information (FDA)


• Rybix ODT Orally Disintegrating Tablets MedFacts Consumer Leaflet (Wolters Kluwer)


• Rybix ODT Advanced Consumer (Micromedex) - Includes Dosage Information


• ConZip Prescribing Information (FDA)


• ConZip Extended-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)


• Ryzolt Consumer Overview


• Ryzolt Prescribing Information (FDA)


• Ryzolt Extended-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)


• Tramadol MedFacts Consumer Leaflet (Wolters Kluwer)


• Tramadol Hydrochloride Monograph (AHFS DI)


• Ultram Consumer Overview


• Ultram Prescribing Information (FDA)


• Ultram ER Prescribing Information (FDA)

Compare Rybix ODT with other medications

• Back Pain
• Pain

Where can I get more information?

• Your pharmacist can provide more information about tramadol.

See also: Rybix ODT side effects (in more detail)

Konsuben

Konsuben may be available in the countries listed below.

Ingredient matches for Konsuben

Sodium Picosulfate

Sodium Picosulfate monohydrate (a derivative of Sodium Picosulfate) is reported as an ingredient of Konsuben in the following countries:

• Japan

International Drug Name Search

Féliderm

Féliderm may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Féliderm

Megestrol

Megestrol 17α-acetate (a derivative of Megestrol) is reported as an ingredient of Féliderm in the following countries:

• France

International Drug Name Search

Avicas

Avicas may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Avicas

Febantel

Febantel is reported as an ingredient of Avicas in the following countries:

• Netherlands


• Portugal

International Drug Name Search

Arret

Arret may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Arret

Loperamide

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Arret in the following countries:

• United Kingdom

International Drug Name Search

Levocomp

Levocomp may be available in the countries listed below.

Ingredient matches for Levocomp

Carbidopa

Carbidopa monohydrate (a derivative of Carbidopa) is reported as an ingredient of Levocomp in the following countries:

• Germany

Levodopa

Levodopa is reported as an ingredient of Levocomp in the following countries:

• Germany

International Drug Name Search

Tedol

Tedol may be available in the countries listed below.

Ingredient matches for Tedol

Ketoconazole

Ketoconazole is reported as an ingredient of Tedol in the following countries:

• Portugal

International Drug Name Search

Digoxin Dak

Digoxin Dak may be available in the countries listed below.

Ingredient matches for Digoxin Dak

Digoxin

Digoxin is reported as an ingredient of Digoxin Dak in the following countries:

• Denmark

International Drug Name Search

Benzosept

Benzosept may be available in the countries listed below.

Ingredient matches for Benzosept

Benzododecinium

Benzododecinium bromide (a derivative of Benzododecinium) is reported as an ingredient of Benzosept in the following countries:

• Tunisia

International Drug Name Search

Americaine

In the US, Americaine (benzocaine topical) is a member of the drug class topical anesthetics and is used to treat Anal Itching and Hemorrhoids.

US matches:

• Americaine Ointment


• Americaine Otic Drops


• Americaine


• Americaine Anesthetic Lubricant


• Americaine Hemorrhoidal

Ingredient matches for Americaine

Benzocaine

Benzocaine is reported as an ingredient of Americaine in the following countries:

• United States

International Drug Name Search

Impamid

Impamid may be available in the countries listed below.

Ingredient matches for Impamid

Indapamide

Indapamide is reported as an ingredient of Impamid in the following countries:

• Bulgaria


• Romania

International Drug Name Search

K+ Care

Ingredient matches for K+ Care

Potassium Chloride

Potassium Chloride is reported as an ingredient of K+ Care in the following countries:

• United States

Potassium Hydrogencarbonate

Potassium Hydrogencarbonate is reported as an ingredient of K+ Care in the following countries:

• United States

International Drug Name Search

Artose

Artose may be available in the countries listed below.

Ingredient matches for Artose

Celecoxib

Celecoxib is reported as an ingredient of Artose in the following countries:

• Vietnam

International Drug Name Search

Supdel

Supdel may be available in the countries listed below.

Ingredient matches for Supdel

Ketotifen

Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Supdel in the following countries:

• Japan

International Drug Name Search

Fluoxetina Decrox

Fluoxetina Decrox may be available in the countries listed below.

Ingredient matches for Fluoxetina Decrox

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetina Decrox in the following countries:

• Spain

International Drug Name Search

Fosmalin

Fosmalin may be available in the countries listed below.

Ingredient matches for Fosmalin

Fosfomycin

Fosfomycin is reported as an ingredient of Fosmalin in the following countries:

• Japan

International Drug Name Search

Glicerolo

Glicerolo may be available in the countries listed below.

Ingredient matches for Glicerolo

Glycerol

Glycerol is reported as an ingredient of Glicerolo in the following countries:

• Greece

International Drug Name Search

Axigem

Axigem may be available in the countries listed below.

Ingredient matches for Axigem

Gemcitabine

Gemcitabine hydrochloride (a derivative of Gemcitabine) is reported as an ingredient of Axigem in the following countries:

• Germany

International Drug Name Search

Saspryl

Saspryl may be available in the countries listed below.

Ingredient matches for Saspryl

Aspirin

Acetylsalicylic Acid is reported as an ingredient of Saspryl in the following countries:

• Israel

International Drug Name Search

Estival

Estival may be available in the countries listed below.

Ingredient matches for Estival

Carbocisteine

Carbocisteine is reported as an ingredient of Estival in the following countries:

• Greece


• Romania

International Drug Name Search

Decostriol

Decostriol may be available in the countries listed below.

Ingredient matches for Decostriol

Calcitriol

Calcitriol is reported as an ingredient of Decostriol in the following countries:

• Germany


• Malaysia

International Drug Name Search

Phil Pharmawealth Omeprazole

Phil Pharmawealth Omeprazole may be available in the countries listed below.

Ingredient matches for Phil Pharmawealth Omeprazole

Omeprazole

Omeprazole is reported as an ingredient of Phil Pharmawealth Omeprazole in the following countries:

• Philippines

International Drug Name Search

Doxazosin

Pronunciation: dox-AZ-oh-sin
Generic Name: Doxazosin
Brand Name: Cardura

Doxazosin is used for:

Treating high blood pressure and treating signs and symptoms of benign prostatic hyperplasia (BPH).

Doxazosin is an alpha-blocker. It works by relaxing muscles in the blood vessels, resulting in lowering of blood pressure. In men with BPH, alpha-blockers work by relaxing muscles around the urethra (the tube that drains urine from the bladder), which improves urinary symptoms.

Do NOT use Doxazosin if:

• you are allergic to any ingredient of Doxazosin or to similar medicines (eg, prazosin)

Contact your doctor or health care provider right away if any of these apply to you.

Before using Doxazosin:

Some medical conditions may interact with Doxazosin. Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of prostate cancer, kidney or liver problems, or high or low blood pressure


• if you will be having eye surgery

Some MEDICINES MAY INTERACT with Doxazosin. Tell your health care provider if you are taking any other medicines, especially any of the following.

• Phosphodiesterase type 5 inhibitors (eg, sildenafil, vardenafil) because severe low blood pressure may occur


• Clarithromycin, HIV protease inhibitors (eg, ritonavir), itraconazole, ketoconazole, nefazodone, telithromycin, or voriconazole because they may increase the risk of Doxazosin's side effects

This may not be a complete list of all interactions that may occur. Ask your health care provider if Doxazosin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Doxazosin:

Use Doxazosin as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Doxazosin by mouth with or without food.


• Doxazosin may cause a sudden drop in blood pressure after the first dose. Take your first dose at bedtime. If you get up during the night, sit up slowly, then stand slowly.


• If you miss a dose of Doxazosin, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Doxazosin.

Important safety information:

• Doxazosin may cause drowsiness, dizziness, lightheadedness, or fainting. These effects may be worse if you take it with alcohol or certain medicines. Use Doxazosin with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Doxazosin may cause a sudden drop in blood pressure after the first dose. Take your first dose at bedtime. If you get up during the night, sit up slowly, then stand slowly. This will help to reduce your lightheadedness or dizziness. These effects will more likely occur after the first few doses or if your dose has increased, but can occur at any time while you are taking the medicine. It can also occur if you stop taking the medicine and then restart treatment.


• Doxazosin may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.


• Do NOT take more than the recommended dose without checking with your doctor.


• Tell your doctor or dentist that you take Doxazosin before you receive any medical or dental care, emergency care, or surgery (including eye surgery).


• Doxazosin may rarely cause a prolonged, painful erection. This could happen even when you are not having sex. If this is not treated right away, it could lead to permanent sexual problems such as impotence. Contact your doctor right away if this happens.


• Patients who take medicine for high blood pressure often feel tired or run down for a few weeks after starting treatment. Be sure to take your medicine even if you may not feel "normal." Tell your doctor if you develop any new symptoms.


• Lab tests, including blood pressure, may be performed while you use Doxazosin. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Doxazosin with caution in the ELDERLY; they may be more sensitive to its effects, especially low blood pressure.


• Doxazosin should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Doxazosin while you are pregnant. It is not known if Doxazosin is found in breast milk. If you are or will be breast-feeding while you use Doxazosin, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Doxazosin:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dizziness; drowsiness; lightheadedness; nasal congestion; tiredness; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; fainting; irregular heartbeat; prolonged, painful erection; severe or prolonged dizziness or headache; shortness of breath; swelling of the ankles, feet, or hands; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Doxazosin side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include severe drowsiness; severe headache or dizziness.

Proper storage of Doxazosin:

Store Doxazosin at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Doxazosin out of reach of children and away from pets.

General information:

• If you have any questions about Doxazosin, please talk with your doctor, pharmacist, or other health care provider.


• Doxazosin is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Doxazosin. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Doxazosin resources

• Doxazosin Side Effects (in more detail)
• Doxazosin Use in Pregnancy & Breastfeeding
• Drug Images
• Doxazosin Drug Interactions
• Doxazosin Support Group
• 11 Reviews for Doxazosin - Add your own review/rating

• Doxazosin Prescribing Information (FDA)


• doxazosin Advanced Consumer (Micromedex) - Includes Dosage Information


• Cardura Prescribing Information (FDA)


• Cardura Monograph (AHFS DI)


• Cardura Consumer Overview


• Cardura XL Prescribing Information (FDA)

Compare Doxazosin with other medications

• Benign Prostatic Hyperplasia
• High Blood Pressure
• Raynaud's Syndrome

Votalin Emulgel

Votalin Emulgel may be available in the countries listed below.

Ingredient matches for Votalin Emulgel

Diclofenac

Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Votalin Emulgel in the following countries:

• China

International Drug Name Search

Pentatop

Pentatop may be available in the countries listed below.

Ingredient matches for Pentatop

Cromoglicic Acid

Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Pentatop in the following countries:

• Germany

International Drug Name Search

Neo-Tiroimade

Neo-Tiroimade may be available in the countries listed below.

Ingredient matches for Neo-Tiroimade

Liothyronine

Liothyronine sodium salt (a derivative of Liothyronine) is reported as an ingredient of Neo-Tiroimade in the following countries:

• Portugal

International Drug Name Search

Paracetamolo Unifarm

Paracetamolo Unifarm may be available in the countries listed below.

Ingredient matches for Paracetamolo Unifarm

Paracetamol

Paracetamol is reported as an ingredient of Paracetamolo Unifarm in the following countries:

• Italy

International Drug Name Search

Captopril-Actavis plus

Captopril-Actavis plus may be available in the countries listed below.

Ingredient matches for Captopril-Actavis plus

Captopril

Captopril is reported as an ingredient of Captopril-Actavis plus in the following countries:

• Germany

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Captopril-Actavis plus in the following countries:

• Germany

International Drug Name Search

Insulin Human, Isophane

Insulin Human, Isophane may be available in the countries listed below.

Ingredient matches for Insulin Human, Isophane

Insulin, Isophane

Insulin Human, Isophane (USP) is also known as Insulin, Isophane (Rec.INN)

International Drug Name Search

Glossary

Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USP	Pharmacopoeia of the United States

Click for further information on drug naming conventions and International Nonproprietary Names.

Sinvastatina Generis

Sinvastatina Generis may be available in the countries listed below.

Ingredient matches for Sinvastatina Generis

Simvastatin

Simvastatin is reported as an ingredient of Sinvastatina Generis in the following countries:

• Portugal

International Drug Name Search

Sertralin Bluefish

Sertralin Bluefish may be available in the countries listed below.

Ingredient matches for Sertralin Bluefish

Sertraline

Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertralin Bluefish in the following countries:

• Germany


• Sweden

International Drug Name Search

Rosula NS Medicated Pads

Pronunciation: sul-fa-SEE-ta-mide/yoor-EE-a
Generic Name: Sulfacetamide/Urea
Brand Name: Rosula NS

Rosula NS Medicated Pads are used for:

Treating certain skin conditions (eg, seborrheic dermatitis) and certain bacterial infections of the skin. It may also be used for other conditions as determined by your doctor.

Rosula NS Medicated Pads are a sulfonamide antibiotic. It works by killing bacteria.

Do NOT use Rosula NS Medicated Pads if:

• you are allergic to any ingredient in Rosula NS Medicated Pads


• you have had a severe allergic reaction (eg, severe rash, hives, difficulty breathing, dizziness) to any other sulfonamide medicine, such as acetazolamide, celecoxib, certain diuretics (eg, hydrochlorothiazide), glyburide, probenecid, sulfamethoxazole, valdecoxib, or zonisamide


• you are taking methenamine

Contact your doctor or health care provider right away if any of these apply to you.

Before using Rosula NS Medicated Pads:

Some medical conditions may interact with Rosula NS Medicated Pads. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of lupus

Some MEDICINES MAY INTERACT with Rosula NS Medicated Pads. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Silver-containing products (eg, silver sulfadiazine) because they may decrease Rosula NS Medicated Pads's effectiveness


• Methenamine because it may increase the risk of Rosula NS Medicated Pads's side effects

This may not be a complete list of all interactions that may occur. Ask your health care provider if Rosula NS Medicated Pads may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Rosula NS Medicated Pads:

Use Rosula NS Medicated Pads as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Rosula NS Medicated Pads are for use on the skin only. Wash and completely dry the affected area. Gently apply the medicated pad to the affected area as directed by your doctor. Wash your hands immediately after using Rosula NS Medicated Pads unless your hands are part of the treated area.


• To clear up your infection completely, use Rosula NS Medicated Pads for the full course of treatment. Keep using it even if you feel better in a few days.


• Rosula NS Medicated Pads works best if it is used at the same time each day.


• Continue to use Rosula NS Medicated Pads even if you feel well. Do not miss any doses.


• If you miss a dose of Rosula NS Medicated Pads, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Rosula NS Medicated Pads.

Important safety information:

• It may take several days for Rosula NS Medicated Pads to work fully.


• Avoid getting Rosula NS Medicated Pads in your eyes, nose, or mouth.


• Talk with your doctor before you use any other medicines or cleansers on your skin.


• Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occur. Do not treat diarrhea without first checking with your doctor.


• Rosula NS Medicated Pads only works against bacteria; it does not treat viral infections.


• Be sure to use Rosula NS Medicated Pads for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.


• Long-term or repeated use of Rosula NS Medicated Pads may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.


• Rosula NS Medicated Pads should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Rosula NS Medicated Pads while you are pregnant. It is not known if Rosula NS Medicated Pads are found in breast milk after topical use. If you are or will be breast-feeding while you use Rosula NS Medicated Pads, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Rosula NS Medicated Pads:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Irritation, stinging, or burning of the skin.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody diarrhea; fever; joint pain; red, swollen, or blistered skin; severe diarrhea; sores in the mouth; stomach cramps/pain.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Rosula NS side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Rosula NS Medicated Pads may be harmful if swallowed. Symptoms of ingestion may include change in the amount of urine; nausea; vomiting.

Proper storage of Rosula NS Medicated Pads:

Store Rosula NS Medicated Pads at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Do not freeze. Keep Rosula NS Medicated Pads out of the reach of children and away from pets.

General information:

• If you have any questions about Rosula NS Medicated Pads, please talk with your doctor, pharmacist, or other health care provider.


• Rosula NS Medicated Pads are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Rosula NS Medicated Pads. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Rosula NS resources

• Rosula NS Side Effects (in more detail)
• Rosula NS Use in Pregnancy & Breastfeeding
• Rosula NS Support Group
• 0 Reviews for Rosula NS - Add your own review/rating

Compare Rosula NS with other medications

• Dandruff
• Seborrheic Dermatitis
• Secondary Cutaneous Bacterial Infections

Niconas

Niconas may be available in the countries listed below.

Ingredient matches for Niconas

Etodolac

Etodolac is reported as an ingredient of Niconas in the following countries:

• Japan

International Drug Name Search

Siloxan

Siloxan may be available in the countries listed below.

Ingredient matches for Siloxan

Simeticone

Simeticone is reported as an ingredient of Siloxan in the following countries:

• Norway

International Drug Name Search

Flexfree

Flexfree may be available in the countries listed below.

Ingredient matches for Flexfree

Felbinac

Felbinac is reported as an ingredient of Flexfree in the following countries:

• Belgium


• Luxembourg

International Drug Name Search

Microsol

Microsol may be available in the countries listed below.

Ingredient matches for Microsol

Lithium

Lithium bromide (a derivative of Lithium) is reported as an ingredient of Microsol in the following countries:

• France

International Drug Name Search

Pseudotumor Cerebri Medications

Definition of Pseudotumor Cerebri: Pseudotumor cerebri literally means "false brain tumor." It is likely due to high pressure within the skull caused by the buildup or poor absorption of cerebrospinal fluid (CSF). The disorder is most common in women between the ages of 20 and 50. Symptoms of pseudotumor cerebri, which include headache, nausea, vomiting, and pulsating sounds within the head, closely mimic symptoms of large brain tumors.

Drugs associated with Pseudotumor Cerebri

The following drugs and medications are in some way related to, or used in the treatment of Pseudotumor Cerebri. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Topics under Pseudotumor Cerebri

• Hypertensive Encephalopathy (0 drugs)

• Intraocular Hypertension (32 drugs in 2 topics)

Learn more about Pseudotumor Cerebri

Micromedex Care Notes:

• Idiopathic Intracranial Hypertension

Medical Encyclopedia:

• Pseudotumor cerebri

Drug List:

Diamox

Diamox-Sequels-Sustained-Release-Capsules

Ticlopidine Poli

Ticlopidine Poli may be available in the countries listed below.

Ingredient matches for Ticlopidine Poli

Ticlopidine

Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Ticlopidine Poli in the following countries:

• Lithuania


• Romania

International Drug Name Search

Sparfloxacine

Sparfloxacine may be available in the countries listed below.

Ingredient matches for Sparfloxacine

Sparfloxacin

Sparfloxacine (DCF) is known as Sparfloxacin in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Femigoa

Femigoa may be available in the countries listed below.

Ingredient matches for Femigoa

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Femigoa in the following countries:

• Germany

Levonorgestrel

Levonorgestrel is reported as an ingredient of Femigoa in the following countries:

• Germany

International Drug Name Search

Spironolactone Apotex

Spironolactone Apotex may be available in the countries listed below.

Ingredient matches for Spironolactone Apotex

Spironolactone

Spironolactone is reported as an ingredient of Spironolactone Apotex in the following countries:

• Belgium

International Drug Name Search

Ethinyloestradiol

Ethinyloestradiol may be available in the countries listed below.

Ingredient matches for Ethinyloestradiol

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Ethinyloestradiol in the following countries:

• New Zealand


• United Kingdom

International Drug Name Search

Vermitox

Vermitox may be available in the countries listed below.

Ingredient matches for Vermitox

Mebendazole

Mebendazole is reported as an ingredient of Vermitox in the following countries:

• Bangladesh

International Drug Name Search

Vectoryl Plus

Vectoryl Plus may be available in the countries listed below.

Ingredient matches for Vectoryl Plus

Indapamide

Indapamide is reported as an ingredient of Vectoryl Plus in the following countries:

• South Africa

Perindopril

Perindopril erbumine (a derivative of Perindopril) is reported as an ingredient of Vectoryl Plus in the following countries:

• South Africa

International Drug Name Search

Octilia

Octilia may be available in the countries listed below.

Ingredient matches for Octilia

Tetryzoline

Tetryzoline is reported as an ingredient of Octilia in the following countries:

• Peru

Tetryzoline hydrochloride (a derivative of Tetryzoline) is reported as an ingredient of Octilia in the following countries:

• Italy


• Russian Federation

International Drug Name Search

Sibulin

Sibulin may be available in the countries listed below.

Ingredient matches for Sibulin

Sibutramine

Sibutramine hydrochloride monohydrate (a derivative of Sibutramine) is reported as an ingredient of Sibulin in the following countries:

• Bangladesh

International Drug Name Search

Orivate

Orivate may be available in the countries listed below.

Ingredient matches for Orivate

Oxybutynin

Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Orivate in the following countries:

• Japan

International Drug Name Search

Barosperse Liquid

barium sulfate

Dosage Form: oral and rectal suspension
LAFAYETTE

LIQUID BAROSPERSE™

BARIUM SULFATE SUSPENSION


Rx only

Barosperse Liquid Description

Liquid Barosperse is a vanilla flavored barium sulfate suspension. It is a contrast medium developed for use in x-ray diagnosis of the gastrointestinal tract.

The product contains 60% w/v barium sulfate USP, suspending agents, flavoring, citric acid, simethicone, potassium sorbate, saccharin sodium and water. Barium sulfate has the empirical formula of BaSO4.

Barosperse Liquid - Clinical Pharmacology

Barium sulfate is an insoluble material which, because of its density, provides a positive contrast during x-ray examination. Barium sulfate is an inert radiopaque material which is not absorbed or metabolized and is eliminated intact from the body in a manner similar to other non-absorbed inorganic materials. Excretion rate is a function of gastrointestinal transit time.

Indications and Usage for Barosperse Liquid

Liquid Barosperse is indicated for use as a contrast medium in x-ray diagnosis of the gastrointestinal tract. The suspension may be administered without dilution for esophageal swallow or filled stomach examinations. Aqueous dilutions may be administered rectally for routine filled colon studies or given orally for filled stomach or enteroclysis procedures.

Contraindications

Barium sulfate products are contraindicated in patients with known or suspected obstruction of the colon, known or suspected gastrointestinal tract perforation, suspected tracheoesophageal fistula, obstructing lesions of the small intestine, pyloric stenosis, inflammation or neoplastic lesions of the rectum, recent rectal biopsy, or known hypersensitivity to barium sulfate formulations.

Barium sulfate suspensions should not be used for infants with swallowing disorders or for newborns with complete duodenal or jejunal obstruction or when distal small bowel or colon obstruction is suspected. Barium sulfate suspension is not recommended for very small preterm infants and young babies requiring small volumes of contrast media or for infants and young children when there is a possibility of leakage from the gastrointestinal tract, such as necrotizing enterocolitis, unexplained pneumoperitoneum, gasless abdomen, other bowel perforation, esophageal perforation or post operative anastomosis.

Known hypersensitivity or allergy to latex is a contraindication for the use of balloon retention enema tips containing latex. The use of a retention cuff enema tip is not necessary or desirable in patients with normal sphincter tone. The presence of adequate sphincter tone can be judged by preliminary rectal digital examination.

Warnings

Serious adverse reactions, including death, have been reported with the administration of barium sulfate formulations and are usually associated with the technique of administration, the underlying pathological condition and/or patient hypersensitivities.

Vomiting following oral administration of barium sulfate may lead to aspiration pneumonitis. Oral administration of barium sulfate suspension by an infant sucking a bottle and administration of large quantities by catheter are reported to be likely to result in aspiration into the tracheobronchial tree. Cardiopulmonary arrest leading to fatality has been reported in infants following aspiration. Aspiration of smaller amounts may cause inflammation.

Barium sulfate preparations used as radiopaque media contain a number of additives to provide diagnostic properties and patient palatability. Allergic responses following the use of barium sulfate suspensions have been reported. Skin irritation, redness, inflammation and hives have been reported for infants and small children following spillage of barium sulfate suspension on their skin. These responses are thought to be caused by the flavors and/or preservatives used in the product.

Barium sulfate suspension has been reported to cause obstruction of the small bowel (impaction) in pediatric patients with cystic fibrosis. It has also been reported to cause fluid overload from the absorption of water during studies in infants when Hirschsprung’s Disease is suspected.

Barium sulfate suspension intravasation can be a serious complication. Mortality has been reported as a result of vaginal or rectal intravasation and is believed to be due to massive pulmonary embolism occurring within minutes of the inciting event.

In patients with increased cranial pressure, barium sulfate suspension enemas present an additional risk of further increasing intracranial pressure.

Care must be taken during the insertion of an enema tip into the patient to prevent application of pressure to the vagus nerve which can lead to vasovagal reactions and syncopal episodes. Cardiac arrhythmia or other cardiovascular side effects can occur as a result of colon distention.

Precautions

General

Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, a family history of allergy, or a previous reaction to a contrast agent warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease.

Anaphylactic and allergic reactions have been reported during double contrast examinations in which glucagon has been used.

An increased risk of perforation has been reported in neonates with intussusception. In patients with cystic fibrosis or blind loops of the bowel or ileus, there is a risk of inspissation leading to partial or complete obstruction.

In neonates and infants with motility disorders such as Hirschsprung’s Disease, retention of large amounts of barium sulfate suspension may result in absorption of water from the suspension and fluid overload. The addition of small amounts of salt to the barium sulfate suspension has been reported to reduce the problem.

Ingestion of barium sulfate suspension is not recommended in patients with a history of food aspiration. If barium sulfate suspension is aspirated into the larynx, further administration of the suspension should be immediately discontinued.

Patient preparation for diagnostic gastrointestinal examinations frequently requires cathartics and a liquid diet. The various preparations can result in water loss for the patient. Patients should be rehydrated quickly following a barium sulfate suspension examination of the gastrointestinal tract. In patients with reduced colon motility, saline cathartics may be required after the barium sulfate suspension enema. Saline cathartics are recommended on a routine basis in patients with a history of constipation unless clinically contraindicated.

Where enema tips are used, care must be taken during insertion into the patient, since forceful or too deep insertion may cause tearing or perforation of the rectum. Insertion of an enema tip should be done only after digital examination by qualified medical personnel. When balloon retention tips are used, care should be taken to avoid overinflation of the balloon, since overfilling or asymmetrical filling may cause displacement of the tip. Such a displacement can lead to rectal perforation or barium sulfate granulomas. Inflation of the balloon should be done under fluoroscopic control by qualified medical personnel. Do not unnecessarily move the enema tip once inserted.

A specially designed enema tip is required for a barium sulfate suspension examination of a colostomy patient.

Intubation of an enteroclysis catheter should be done by qualified medical personnel. Perforation of the duodenum has been reported.

Because of reported anaphylactoid reactions to latex, the use of non-latex gloves during the procedure should be considered.

Pregnancy

Safe use of barium sulfate during pregnancy has not been established. Barium sulfate should be used in pregnant women only if the possible benefits outweigh the potential risks. Elective radiography of the abdomen is considered to be contraindicated during pregnancy due to the risk to the fetus from radiation exposure. Radiation is known to cause harm to the unborn fetus exposed in utero.

Pediatric Use

The radiographic contrast agents used for examination of children do not differ substantially from those used for adults. The variation in physical sizes of pediatric patients requires more thorough attention to individualizing dosage. The volume of barium sulfate suspension and the barium sulfate content required will also depend upon the technique used and the clinical need.

Adverse Reactions

Adverse reactions accompanying the use of barium sulfate formulations are infrequent and usually mild, though severe reactions (approximately 1 in 500,000) and fatalities (approximately 1 in 2,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium sulfate impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. EKG changes have been shown to occur following or during barium sulfate suspension enemas. It is of the utmost importance to be completely prepared to treat any such occurrence.

Due to the increased likelihood of allergic reactions in atopic patients, a complete history of known and suspected allergies as well as allergic-like symptoms, such as rhinitis, bronchial asthma, eczema and urticaria, must be obtained prior to any medical procedure.

Aspiration of large amounts of barium sulfate suspension may cause pneumonitis or nodular granulomas of interstitial lung tissues and lymph nodes; asphyxiation and death have been reported.

Transient bacteremia, beginning almost immediately and lasting up to 15 minutes, may also occur during rectal administration of barium sulfate suspension, and rarely septicemia has been reported.

A rare mild allergic reaction would most likely be generalized pruritis, erythema or urticaria (approximately 1 in 100,000 reactions). Such reactions will respond to an antihistamine. More serious reactions (approximately 1 in 500,000) may result in laryngeal edema, bronchospasm or hypotension.

Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, bronchospasm, agitation, confusion and cyanosis, progressing to unconsciousness. Treatment should be initiated immediately according to established standard of care.

Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature.

Allergic reactions to the enema accessories, in particular to retention catheters (tips) with latex cuffs, can occur. Such reactions could occur immediately and result in the previously mentioned acute allergic-like responses or might be delayed in appearance and result in a contact dermatitis. Known atopic patients, particularly those with a history of asthma or eczema, should be evaluated for alternative methods of administration in order to avoid these adverse reactions. These plastic/rubber accessories are disposable, single-use devices that must not be reused or left in the body cavity for an extended period of time.

Postmarketing Experiences

The following adverse experiences have been reported in patients receiving products containing barium sulfate. These adverse experiences are listed alphabetically: abdominal cramping, abdominal pain, diarrhea, fever, foreign body trauma relating to procedural complications, headache, laryngeal burning and irritation, leukocytosis, procedural site reactions, rash, and vomiting.

Overdosage

In rare instances, immediate repeat oral examinations utilizing standard dosages may lead to severe stomach cramps and diarrhea. Cases reported implicate a total dose in the range of 30 ounces (900 mL) of suspension. Instances of this type have resolved spontaneously and they are not considered to be life-threatening.

Barosperse Liquid Dosage and Administration

Patient Preparation

Successful examination of the upper gastrointestinal tract requires that the stomach be empty and essentially free of fluid. This can usually be accomplished by instructing the patient to abstain from eating or drinking anything after the evening meal before the examination. The preparation for small bowel examinations, done separately or combined with an upper gastrointestinal series, is the same.

For examinations of the colon, the patients should be given a low solid diet for a minimum of 24 hours before the examination. Laxatives should also be used to clean the colon. In order to obtain thorough cleansing of the colon, a 2 liter water enema one hour before the examination may be necessary.

Administration

Individual technique will determine the suspension quantity and barium sulfate content to be used. The following dilutions are suggested for Liquid Barosperse.

EXAMINATION	DILUTION FORMULA	% BARIUM SULFATE (w/v)
Filled Stomach	Use undiluted or	60%
	3 parts Liquid Barosperse to 1 part water	45%
Esophageal Swallow	Use undiluted	60%
Enteroclysis	3 Parts Liquid Barosperse to 1 part water	45%
Routine Filled Colon	1 part Liquid Barosperse to 2 parts water	20%

Shake well before using.

It is recommended that Liquid Barosperse be served chilled for upper gastrointestinal studies. This will give a more rapid transit of Liquid Barosperse from the stomach into the small bowel. For lower gastrointestinal studies, Liquid Barosperse should be administered at room temperature to body temperature.

Pediatric Use

The quantity of suspension used and the barium sulfate concentration will depend upon patient size, technique used and clinical need.

For single patient use only. Properly discard unused portion.

How is Barosperse Liquid Supplied

Catalog No. 179312. NDC 68240-325-24. 355 mL bottles. Twenty-four (24) bottles and twenty-four (24) straws per case.

Store at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). Protect from freezing.

Liquid Barosperse is a trademark of Mallinckrodt Inc. or its subsidiaries.

DIN: 02196190

Distributed in Canada by:

tyco Healthcare

Pointe-Claire, QC, Canada H9R 5H8

Establishment License # 100689-A

Made in Mexico

Manufactured by:

Mallinckrodt Inc.

St. Louis, MO 63042 USA

www.Mallinckrodt.com

SINGLE CONTRAST

UPPER G.I.

• Ready-to-use


• Flavored


• Dilute for lower G.I. exams

MID 1304685

Rev. 02/2009

tyco

Healthcare

Mallinckrodt

Package Label - Principal Display Panel - 355 mL Bottle

L A F A Y E T T E

LIQUID BAROSPERSE™

BARIUM SULFATE

SUSPENSION

Catalog No. 179312

O3™ ANTIMICROBIAL TECHNOLOGY

UPPER G.I. EXAMS

Rx only

355 mL

LIQUID BAROSPERSE

Barium Sulfate Suspension USP

NDC 68240-325-24

Catalog No. 179312

A vanilla flavored 60% w/v barium sulfate USP suspension for use in x-ray diagnosis of the gastrointestinal tract.

Contents: Barium sulfate USP, suspending agents, flavoring, citric acid, simethicone, potassium sorbate, saccharin sodium and water.

Contraindications: Do not use in patients with suspected gastrointestinal tract

perforation or known hypersensitivity to barium sulfate formulations.

Dosage and Administration: See package insert for complete instructions. See box below for mixing directions. Individual technique will determine the suspension quantity and barium sulfate content to be used. The following dilutions are suggested for Liquid Barosperse.

EXAMINATION	DILUTION FORMULA	% BARIUM SULFATE (w/v)
Filled Stomach	Use undiluted or	60%
	3 parts Liquid Barosperse to 1 part water	45%
Esophageal Swallow	Use undiluted	60%
Enteroclysis	3 Parts Liquid Barosperse to 1 part water	45%
Routine Filled Colon	1 part Liquid Barosperse to 2 parts water	20%

For single patient use only. Properly discard unused portion.

Storage: Store at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). Protect from freezing. Shake well before using.

Net Contents: 355 mL (12 fl. oz.)

DIN: 02196190

Distributed in

Canada by:

tyco Healthcare

Pointe-Claire, QC

Canada H9R 5H8

Establishment

License # 100689-A

Made in Mexico

Manufactured by:

Mallinckrodt Inc.

St. Louis, MO 63042 USA

www.Mallinckrodt.com

MID 1170125

Rev. 02/2009

tyco/Healthcare

MALLINCKRODT

LIQUID BAROSPERSE  barium sulfate  suspension

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 68240-325 Route of Administration ORAL, RECTAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength BARIUM SULFATE (BARIUM CATION) BARIUM SULFATE 600 mg  in 1 mL

Inactive Ingredients Ingredient Name Strength SACCHARIN SODIUM   SODIUM HYPOCHLORITE   POTASSIUM SORBATE   WATER   HYDROGEN PEROXIDE   CROSCARMELLOSE SODIUM   ANHYDROUS CITRIC ACID   BENTONITE   VANILLA

Product Characteristics Color      Score      Shape Size Flavor VANILLA Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 68240-325-24 24 BOTTLE In 1 CASE contains a BOTTLE, PLASTIC 1 355 mL In 1 BOTTLE, PLASTIC This package is contained within the CASE (68240-325-24)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		06/01/2009	09/30/2012

Labeler - Mallinckrodt, Inc. (810407189)

Establishment
Name	Address	ID/FEI	Operations
Mallinckrodt Medical, S.A. de C.V.		810407189	analysis, manufacture

Revised: 08/2010Mallinckrodt, Inc.

More Barosperse Liquid resources

• Barosperse Liquid Side Effects (in more detail)
• Barosperse Liquid Use in Pregnancy & Breastfeeding
• Barosperse Liquid Support Group
• 0 Reviews for Barosperse - Add your own review/rating

Compare Barosperse Liquid with other medications

• Computed Tomography